Welcome to the SWSLHD Libraries Research Repository, an institutional repository which showcases the research output of South Western Sydney Local Health District staff, both past and present. The repository supports the SWSLHD Strategic Plan in their vision for the SWSLHD to be a leader in research and innovation.
Please use this identifier to cite or link to this item:
https://swslhd.intersearch.com.au/swslhdjspui/handle/1/13035| Title: | WHAT ARE THE RISKS OF BIOLOGIC THERAPIES AND HOW DO YOU COMMUNICATE THEM TO PATIENTS? |
| Author: | Connor, S. Wu, Y. C. |
| Issue Date: | 2024 |
| Journal: | Curbside Consultation in IBD: 49 Clinical Questions |
| Abstract: | The range of biologic therapies currently available for treating inflammatory bowel disease (IBD) include anti-tumor necrosis factor (anti-TNF) agents, infliximab, adalimumab, certolizumab, and golimumab; one anti-adhesion molecule, vedolizumab; and one interleukin (IL) 12/IL-23 antagonist, ustekinumab. The foundation of selecting the optimal treatment for a patient with IBD rests in individualized assessment of a patient?s risk-to-benefit ratio. � 2022 by Taylor & Francis Group. |
| ISSN: | 978-104013849-6 (ISBN); 978-163091650-3 (ISBN) |
| Digital object identifier: | 10.1201/9781003523567-23 |
| URI: | https://swslhd.intersearch.com.au/swslhdjspui/handle/1/13035 |
| Appears in Collections: | Liverpool Hospital |
Files in This Item:
There are no files associated with this item.
Items in Prosentient are protected by copyright, with all rights reserved, unless otherwise indicated.
